Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The site revision label changed from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-21T21:13:11.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The clinical trial record for nivolumab and oral cyclophosphamide in relapsed/refractory AML and higher-risk MDS is displayed, with study design, participant criteria, treatment details, outcomes, and supporting documents.
    Difference
    52%
    Check dated 2026-11-08T02:00:06.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The study record still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T21:02:51.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    A notice about NIH websites transitioning from “Artificial Intelligence” to “Super Intelligence” appears above the page content.
    Difference
    1%
    Check dated 2026-10-24T22:11:04.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T21:00:35.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The footer’s site revision indicator changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T21:48:44.000Z thumbnail image

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.